MDACC Study No:2011-1058 ( NCT No: NCT01629498)
Title:Phase I/II trial of image-guided, intensity-modulated photon (IMRT) or scanning beam proton therapy (IMPT) both with simultaneous integrated boost (SIB) dose escalation to the gross tumor volume (GTV) with concurrent chemotherapy for stage II/III non-small cell lung cancer (NSCLC)
Principal Investigator:Zhongxing Liao
Treatment Agent:Chemoradiotherapy; Proton Therapy
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the dose of radiation
to the tumor but not the surrounding healthy tissue could be increased by using
intensity-modulated photon therapy (IMRT) or intensity-modulated proton beam
therapy (IMPT).

In Phase I of the study, researchers want to find the highest tolerable dose of
IMPT or IMRT that can be given to the tumor.

In Phase II, researchers want to learn if IMPT can help to control the disease
compared with standard proton therapy when both are combined with standard
chemotherapy. Participants will also receive standard chemotherapy. Proton
therapy and photon therapy are types of radiation therapy that are designed to
use a beam of proton or photon particles (similar to getting an x-ray) to send
radiation inside the body to the tumor.

In IMPT and IMRT, the amount or strength of the protons or photons will be
adjusted according to the size, shape, and thickness of the tumor. In this
study, the tumor will receive a higher dose by adjusting the energy and
scanning time of the protons or photons, which is called simultaneous
integrated boost (SIB). The treatment will be done with image guidance. This
newer type of radiation is designed to give a higher than standard dose of
treatment to the tumor. It is also designed to focus the treatment on the
tumor to avoid affecting the healthy tissue around the tumor as much as
standard treatments.
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase I/Phase II
Treatment Agents:Chemoradiotherapy
Proton Therapy
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Massachusetts General Hospital
National Cancer Institute
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Zhongxing Liao
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults